Results 61 to 70 of about 6,850 (200)

Digital Phenotyping and Lifestyle Intervention in Patients With Myasthenia Gravis (DIG‐MG): A Randomized Controlled Trial of Feasibility, Adherence, and Effects on Fatigue

Muscle &Nerve, Volume 74, Issue 1, Page 92-102, July 2026.
ABSTRACT Introduction/Aims Physical activity and sleep influence fatigue in myasthenia gravis (MG), and digital health technologies (DHT) enable objective monitoring of these behaviors in daily life. Using this approach, we evaluated whether a lifestyle intervention targeting physical activity or sleep hygiene could reduce fatigue in MG.
Maja Norling, Niclas Eriksson, Elisabet Westerberg, Ingela Nygren, Klara Norman, Julia Hedberg, Sui H. Wong, Susanna Jernelöv, Pernilla Åsenlöf, Anna Rostedt Punga   +9 more
wiley   +1 more source

Distal Agrin (AGRN) Congenital Myasthenic Syndrome With Mitochondrial Dysfunction

European Journal of Neurology, Volume 33, Issue 7, July 2026.
ABSTRACT Background Agrin‐congenital myasthenic syndrome (AGRN‐CMS) is a rare, heterogeneous genetic disorder of the neuromuscular transmission that can present from infancy to adulthood. The clinical phenotype includes distal weakness mimicking distal myopathies.
Mariana Manoel Oku, Zhiyv Niu, Duygu Selcen, William J. Litchy, Margherita Milone   +4 more
wiley   +1 more source

Treatment of Ocular Myasthenia Gravis

Asia-Pacific Journal of Ophthalmology, 2019
Myasthenia gravis is a relatively common neuromuscular disorder, with ocular myasthenia gravis being a subset defined as myasthenia gravis limited to the orbicularis, levator, and extraocular muscles. Patients with ocular myasthenia gravis can have disabling diplopia or functional blindness from ptosis and in most cases treatment is required.
openaire   +2 more sources

Remote Monitoring in Myasthenia Gravis: Exploring Symptom Variability

Annals of Clinical and Translational Neurology, Volume 13, Issue 6, Page 1106-1117, June 2026.
ABSTRACT Background Myasthenia gravis (MG) is a rare, autoimmune disorder characterized by fluctuating muscle weakness and potential life‐threatening crises. While continuous specialized care is essential, access barriers often delay timely interventions. To address this, we developed MyaLink, a telemedical platform for MG patients.
Maike Stein, Maximilian Mönch, Meret Herdick, Frauke Stascheit, Sarah Hoffmann, Hannah Preßler, Philipp Mergenthaler, Carla Dusemund, Paolo Doksani, Haoqi Sun, Pushpa Narayanaswami, Andreas Meisel, Lea Gerischer, Sophie Lehnerer   +13 more
wiley   +1 more source

A Central Somatic Transmission Mediates Proprioceptive Facilitation of Muscle Pain

Advanced Science, Volume 13, Issue 34, 19 June 2026.
Zhang et al. uncover a novel central mechanism for persistent muscle pain, in which TRPA1 sensitization in MeV proprioceptive neurons enhances somatic secretion. This, in turn, disinhibits descending pain control from neighboring noradrenergic locus coeruleus neurons via local GABAergic circuits, thereby promoting inflammatory muscle pain.
Xiaoyu Zhang, Jiale Yang, Xi Wu, Jie Li, Fujian Lu, Yiman Li, Xingyu Du, Rong Huang, Jamila Asgar, Jing Wang, Ke Ren, Feipeng Zhu, Changhe Wang, Yehua Gan, Feng Wei, Zhuan Zhou   +15 more
wiley   +1 more source

Familial Autoimmune Myasthenia Gravis (Report Of 3 Cases)

Annals of Indian Academy of Neurology, 2003
Familial Autoimmune myasthenia gravis is rare, occurring in only about 1.3% cases of myasthenia gravis (MG). Here in we report a family with three family members affected by MG. Proband presented with generalised myasthenia where as the other two
Girija A. S, Madhukar M, John John K
doaj  

Disease Remission: A Scoping Review With Thematic Analysis of the Scientific Literature With Implications for Chronic Rhinosinusitis

International Forum of Allergy &Rhinology, Volume 16, Issue 6, Page 615-629, June 2026.
ABSTRACT Background Remission, a term used to describe a goal of treatment for some chronic diseases, has recently been proposed for chronic rhinosinusitis (CRS). However, it is unclear what remission means for CRS and why it should serve as a goal in the present‐day treatment of CRS.
Nikhil Parail, Lynn Warner, Stacey T. Gray, Claire Hopkins, Peter H. Hwang, Sarah K. Wise, Katie M. Phillips, Ahmad R. Sedaghat   +7 more
wiley   +1 more source

Single-fiber electromyography in the orbicularis oculi muscle in patients with ocular myasthenia gravis symptoms: does abnormal jitter predict response to treatment?

BMC Neurology, 2017
Background Seronegative ocular myasthenia gravis (OMG) is diagnosed by ocular symptoms with supporting SFEMG, typically of frontalis or extensor digitorum muscles.
Goran Rakocevic, Mark Moster, Mary Kay Floeter   +2 more
doaj   +1 more source

Comparing Efficacy and Safety of Various Monoclonal Antibodies in Myasthenia Gravis: A Systematic Review and Network Meta‐Analysis of Randomized Controlled Trials

Brain and Behavior, Volume 16, Issue 6, June 2026.
ROZ 10 mg/kg ranked best for reducing MG‐ADL. BAT 680 mg significantly reduced QMG and ranked best. BAT 340 mg had the highest probability of reducing the MGC score. ECU significantly decreased MG‐QoL 15r and ranked best. BEL 10 mg/kg had the highest likelihood of reducing adverse events.
Muhammad Hassan Waseem, Zain ul Abideen, Minahil Iqbal, Saniya Ishtiaq, Pawan Kumar Thada, Adam A. Dmytriw   +5 more
wiley   +1 more source

Miasthenia gravis in pediatric age

Acta Médica del Centro, 2008
Background: Myasthenia gravis is an autoimmune disorder characterized by fluctuating muscle weakness and fatigue of different muscle groups, secondary to a synaptic transmission alteration caused by the blockade and destruction of the acetylcholine ...
Liubka María Pérez Mederos, María Ofelia Hernández Oliver, Cecilio González Benavides, José Manuel González Santos   +3 more
doaj